Galera Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Malvern PA United States (2009)

Organization Overview

First Clinical Trial
2013
NCT01921426
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Galera Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Avasopasem (14 trials)

Drugs in Phase 2 Trials (1)

gc4711 (3 trials)

Drugs in Phase 1 Trials (3)

dextromethorphan (delsym) (1 trial)

gc4702 (1 trial)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Critical Illness (Phase 2)

Esophagitis (Phase 2)

Head and Neck Neoplasms (Phase 3)

Infections (Phase 2)

Mucositis (Phase 3)

Neoplasms, Squamous Cell (Phase 1)

Pancreatic Neoplasms (Phase 2)

Stomatitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 5